Close
Reuniting the MND community at the 34th International Symposium on ALS/MND

Reuniting the MND community at the 34th International Symposium on ALS/MND

Reading Time: 4 minutes After 3 years of online events, the MND research and healthcare community reunited in-person at the 34th International Symposium on ALS/MND in Basel, Switzerland! From 6 – 8 December 2023, we welcomed back over 1300 delegates, including researchers, health and social care professionals and people living with and affected by MND, becoming one of our…

Can signs of MND be detected before symptoms appear?

Can signs of MND be detected before symptoms appear?

Reading Time: 6 minutes It has been suggested that there might be a pre-symptomatic stage of MND, where the disease is active and occurring within a person but no symptoms are showing. There is currently little research in this area and a lack of evidence of a pre-symptomatic stage of the disease. However, if it can be shown that there is a pre-symptomatic stage which can be measured, this could be very useful in helping people with MND to get treatment as early as possible. Dr Michael Benatar, from the University of Miami, has been looking into this by studying the development of MND and how the disease presents in people who have a high risk of developing it.

The importance of phenotyping

The importance of phenotyping

Reading Time: 4 minutes This is blog number 5 in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green text correspond to the code in the abstract book. Click on the number to be redirected to the full abstract (the page may take a minute to load). The phenotype is the…

Genetics and MND

Genetics and MND

Reading Time: 5 minutes This is blog number two in our ‘Symposium Blogathon’ – counting down to the 32nd International Symposium on ALS/MND. Numbers in bold green text correspond to the code in the abstract book. Click on the number to be redirected to the full abstract (the page may take a minute to load). Approximately 10% of people…

Updates on Tofersen Trials for SOD1-MND

Updates on Tofersen Trials for SOD1-MND

Reading Time: 7 minutes Global biotechnology company Biogen has announced plans to make tofersen, a potential treatment for people whose MND is believed to be driven by mutations in the SOD1 gene, available to more people on an early access programme. Biogen have also revealed that they are conducting a new Phase 3 clinical trial of tofersen in those…